News Story: Full Text
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website


   Share  

Management of patients with newly diagnosed malignant primary brain tumors with a focus on the evolving role of temozolomide.


Posted on: 06/04/2008

Ther Clin Risk Manag. 2007 Dec;3(6):1027-33. Related Articles


Management of patients with newly diagnosed malignant primary brain tumors with a focus on the evolving role of temozolomide.

Gilbert MR, Armstrong TS.

Department of Neuro-Oncology, The University of Texas MD, Anderson Cancer Center Houston, TX, USA.

The prognosis for patients with newly diagnosed malignant gliomas remains poor; however there have been some recent advances in treatment that have generated optimism. Medical management usually includes administration of corticosteroids to control peritumoral edema. Anticonvulsants are indicated for patients with established tumor-related seizures; however, the prophylactic use of anticonvulsants remains controversial. Advances in neurosurgical techniques have improved the safety of tumor resection and most patients undergo the maximal safe surgical debulking of tumor. The tissue sample obtained provides conclusive pathologic diagnosis and tumor classification and extensive tumor resection may impact patient outcome. For glioblastoma, external beam radiation had been the conventional first line treatment; however a recent international phase III trial has provided level 1 evidence that a chemoradiation regimen using external beam radiation plus the oral chemotherapy agent temozolomide provides a survival advantage over radiation alone. Correlative studies were also performed that demonstrated better outcomes for patients with tumors demonstrating methylation (inactivation) of the promoter region of methyl guanine methyltransferase (MGMT) gene. Additional studies are in progress building on the clinical trial results using different dosing schedules of temozolomide and combination regimens. Studies are also underway to develop molecular markers, such as expression of MGMT that may help select the patients most likely to benefit from this treatment.

PMID: 18516257 [PubMed - in process]

Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites